Ampligen poly I:poly C12U antiviral data

In a Phase II study, Ampligen added to AZT treatment maintained a higher number of CD4 cells, with better immune function and no increased toxicity to bone marrow, compared to AZT alone.

The one-year trial in 36 HIV-positive patients showed that patients given Ampligen had a greater likelihood (p = 0.042) of positive delayed type hypersensitivity response, an index of intact immune function. In patients with counts greater than 300 on entry to the trial, night sweats and loss of CD4 cells also were ameliorated by the agent (p < 0.005 and 0.04 respectively). ...